Navigation Links
Daiichi Sankyo's Once-Daily Edoxaban Meets Primary Efficacy Endpoint for Stroke Prevention and Superiority for the Principal Safety Endpoint Compared to Warfarin for Patients with Atrial Fibrillation in a Phase 3 Clinical Trial
Date:11/19/2013

sing was applied according to the study protocol. In both edoxaban treatment arms, the edoxaban dose was halved for patients with clinical factors that were known to increase the risk of bleeding (renal impairment, low body weight or concomitant use of certain P-glycoprotein inhibitors).1, 2 Patients receiving a reduced edoxaban dose in the 60 mg treatment arm had an annual incidence of stroke or SEE of 2.32% versus 2.68% for warfarin and a significantly reduced major bleeding incidence of 3.05% versus 4.85%. Patients receiving a reduced edoxaban dose in the 30 mg treatment arm had an annual incidence of stroke or SEE of 3.14% versus 2.68% for warfarin and a significantly reduced major bleeding incidence of 1.50% versus 4.85%.2

"The results from the ENGAGE AF-TIMI 48 trial showed that edoxaban may provide a new treatment option for the prevention of stroke or systemic embolic events that demonstrates comparable efficacy to warfarin, while significantly reducing the risk of major bleeding. In addition, we identified an appropriate dose regimen for patients with clinical factors such as renal impairment and low body weight," said Robert Giugliano, MD, SM, FAHA, FACC, Senior Investigator with the TIMI Study Group, Physician Cardiovascular Medicine, Brigham and Women's Hospital, Associate Professor of Medicine, Harvard Medical School, and Co-Global Lead Investigator of the ENGAGE AF-TIMI 48 trial. "In conducting this landmark trial we sought to provide clinicians with robust data, evident by the trial size and follow-up, high percentage of time in therapeutic range for the warfarin treatment arm, and very low rate of missing data. In addition, we specifically designed a comprehensive transition plan to protect patients from the undue risk of stroke and bleeding when switching to open-label anticoagulation at the end of the trial."

"The edoxaban clinical trial program, the largest in the history of Daiichi
'/>"/>

SOURCE Daiichi Sankyo
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Daiichi Sankyos Once-Daily Edoxaban Shows Comparable Efficacy and Superiority for the Principal Safety Endpoint Compared to Warfarin in a Phase 3 Study for the Treatment of Symptomatic VTE and Prevention of its Recurrence
2. Daiichi Sankyo CEO John Gargiulo Elected as National Pharmaceutical Councils Chairman of the Board
3. Daiichi Sankyo ha completato larruolamento dei pazienti per lo studio Hokusai-VTE su Edoxaban, il più ampio trial clinico di fase 3 per il trattamento delle tromboembolie venose ricorrenti
4. Daiichi Sankyo Completes Enrolment in Hokusai - VTE, investigating once-daily Edoxaban in the Largest Single Phase 3 Study for the Treatment and Prevention of Recurrence of VTE
5. Daiichi Sankyo, Inc. Receives FDA Approval to Package Product at New Facility in Bethlehem, PA
6. Sanofi Announces Positive Phase 3 Data for Once-Daily Lixisenatide for Type 2 Diabetes
7. Upsher-Smith Presents Data Supporting Favorable Tolerability And Consistent Pharmacokinetic Profile Of Once-Daily USL255 (Extended-Release Topiramate)
8. Sosei Group Corporation: QVA149 Filed by Licensing Partner as a Once-Daily Maintenance Treatment for COPD in Japan
9. Sosei Group Corporation: QVA149 Filed as a Once-Daily Maintenance Treatment for COPD in Europe
10. Sosei Group Corporation: Data at ERS Shows Efficacy of Once-daily COPD Portfolio Versus Comparators, Further Establishes Dual-bronchodilator QVA149
11. Coherus Announces CHS-0214 (Proposed Etanercept Biosimilar) Meets Primary Endpoint In Pivotal Pharmacokinetic Clinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 11, 2014 Patient engagement has become ... organizations are turning to an assortment of marketing ... part of this evolving approach to patient engagement, ... and engage patients throughout their experiences with a ... By mapping the patient journey and employing a ...
(Date:7/11/2014)... 11, 2014  Rock Creek Pharmaceuticals, Inc. (NASDAQ: ... that the Food and Drug Administration ("FDA"), has notified ... RCP,s Investigational New Drug ("IND") application before granting the ... US. Dr. Chris Chapman , RCP,s ... on our IND. When we receive the agency,s official ...
(Date:7/11/2014)... DALLAS , July 11, 2014 ... report "Scintillator Market by Composition of Material, Application ... and others), End Product (Personal Instrument, Hand-Held Instruments, ... Forecast and Analysis to 2013 - 2020", published by MarketsandMarkets, ... a CAGR of 5.62% from 2014 to 2020, ...
Breaking Medicine Technology:New Study Uses Six-Step Patient Journey as Framework for Consumer-Focused Marketing Opportunities 2Rock Creek Pharmaceuticals Issues Update On US Investigational New Drug Application 2Scintillator Market will be worth $479.16 Million by 2020 2Scintillator Market will be worth $479.16 Million by 2020 3Scintillator Market will be worth $479.16 Million by 2020 4
... , , , ... (Nasdaq: AMGN ) today announced the publication of results from ... at reducing fracture risk in more than 7,800 women with postmenopausal osteoporosis ... deprivation therapy (ADT) leading to bone loss. In both studies, published today ...
... , , , ... BioPharmaceuticals, Inc., a biotechnology company developing antiviral therapies, announced today that the ... chronically infected with the hepatitis C virus (HCV). The trial, run in ... clemizole monotherapy in the absence of interferon. , , ...
Cached Medicine Technology:Studies Published in the New England Journal of Medicine Highlight Potential New Option in the Treatment of Bone Loss 2Studies Published in the New England Journal of Medicine Highlight Potential New Option in the Treatment of Bone Loss 3Studies Published in the New England Journal of Medicine Highlight Potential New Option in the Treatment of Bone Loss 4Studies Published in the New England Journal of Medicine Highlight Potential New Option in the Treatment of Bone Loss 5Studies Published in the New England Journal of Medicine Highlight Potential New Option in the Treatment of Bone Loss 6Studies Published in the New England Journal of Medicine Highlight Potential New Option in the Treatment of Bone Loss 7Studies Published in the New England Journal of Medicine Highlight Potential New Option in the Treatment of Bone Loss 8Studies Published in the New England Journal of Medicine Highlight Potential New Option in the Treatment of Bone Loss 9Studies Published in the New England Journal of Medicine Highlight Potential New Option in the Treatment of Bone Loss 10Studies Published in the New England Journal of Medicine Highlight Potential New Option in the Treatment of Bone Loss 11Eiger BioPharmaceuticals Announces Initiation of CLEAN-1 HCV Phase 1b Trial 2Eiger BioPharmaceuticals Announces Initiation of CLEAN-1 HCV Phase 1b Trial 3
(Date:7/11/2014)... Miriam Hospital have found that people with mobility ... of smoking than those without mobility impairments. Additionally, ... attempt quitting than those without mobility impairments, and ... this population. The study and its findings are ... American Journal of Public Health . ...
(Date:7/11/2014)... has found that organic foods and crops have ... including more antioxidants and fewer, less frequent pesticide ... 343 peer-reviewed publications comparing the nutritional quality and ... fruits, vegetables, and grains. The study team applied ... and non-organic foods. , "Science marches on," ...
(Date:7/11/2014)... Delaying surgery to repair damage to the anterior cruciate ligament ... knee -- could increase a young athlete,s risk for further ... 130 patients, aged 8 to 16, who had ACL reconstruction ... weeks after their injury, 37 had surgery six to 12 ... months after their injury. The youngsters who had surgery ...
(Date:7/11/2014)... Prostate cancer patients are more likely to be diagnosed ... sooner if they also have depression, a new study ... American men who were diagnosed with localized prostate cancer ... Nearly 1,900 of the patients had been diagnosed with ... was discovered. "Men with intermediate- or high-risk prostate ...
(Date:7/11/2014)... Ticket Down is a reliable ... Train Amphitheatre in Wheatland, CA. In the Sacramento ... what the Sleep Train Amphitheatre can do for music fans. ... over the course of its existence and can seat 18,500 ... in Wheatland (Sacramento metro area) will host the “That’s My ...
Breaking Medicine News(10 mins):Health News:Miriam Hospital study examines smoking prevalence 2Health News:Major study documents nutritional and food safety benefits of organic farming 2Health News:Major study documents nutritional and food safety benefits of organic farming 3Health News:Delaying Kid's Knee Surgery Could Be a Bad Play, Study Finds 2Health News:Depression May Make It Harder to Beat Prostate Cancer 2Health News:Luke Bryan Tickets Sleep Train Amphitheatre in Wheatland, CA (Sacramento): Ticket Down has Slashed Ticket Prices on Luke Bryan in Wheatland at Sleep Train 2Health News:Luke Bryan Tickets Sleep Train Amphitheatre in Wheatland, CA (Sacramento): Ticket Down has Slashed Ticket Prices on Luke Bryan in Wheatland at Sleep Train 3
... of refugees settled in the makeshift relief camps of ... of Chhattisgarh.// ,UNICEF will specifically look into ... settled in these camps. ,According to ... the organisation's representative in India, met Chhattisgarh chief minister ...
... towards water to chill out. Places such as backyard pool, hot ... very for cautious and always follow the instructions of their parents. ... all the safety measures such as installing the pool fences and ... fail to install the child proof safety measures as it is ...
... gay men who have also been diagnosed as HIV-positive seemed ... status to others//. ,The study, the first of ... HIV-positive men who are often uncertain whether to tell friends, ... that causes AIDS. It was published in the April issue ...
... fees for admittance into various medical courses offered by ... education and research department// of the Punjab government. The ... medical and paramedical courses. ,Representatives of medical ... consultation regarding the actual fees to be fixed for ...
... in which the sinuses become inflamed or infected affecting ... conventional surgery//. But now Acclarent has come up with ... a small balloon in the sinus cavity which clears ... breakthrough that offers hope to many sinusitis sufferers. It ...
... High Court has sought an explanation from medical superintendent ... disclosure of sufficient details after a boy, suffering from ... the hospital in 2001. ,Aggrieved with the ... the hospital to explain its unwillingness to disclose details ...
Cached Medicine News:Health News:Hot Tubs and Spas in the News for Safety Measures 2Health News:Gays Have No Regrets 2Health News:Gays Have No Regrets 3Health News:Provisional Fees For Medical Courses Fixed By Punjab Government 2Health News:Teething Problems of Sinuplasty 2
Standard general retractor system. Fully-adjustable to maintain a low profile in any approach and any patient. Blades can be stacked on top of each other in the operative site....
These retractors are packaged singly ready for sterilization at your facility....
... Pipetman Concept is a revolutionary ... and flexibility in mind, Pipetman Concept ... direct pipette-to-PC connectionthe only one of ... used with Diamond Tips from Gilson, ...
... 3 - Vivid family system designed to ... cardiovascular performance, and offer an even wider ... and the OR. , ,From color flow ... connectivity, the new Vivid 3 offers a ...
Medicine Products: